A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia

被引:3
|
作者
Kim, YT [1 ]
Kang, BJ [1 ]
机构
[1] Kyungpook Natl Univ, Sch Med, Dept Psychiat, Taegu 700412, South Korea
关键词
schizophrenia; olanzapine; cognitive function;
D O I
10.1002/hup.584
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The aim of this study was to compare the effects of olanzapine and risperidone on cognitive functions in patients with schizophrenia. The subjects were schizophrenic outpatients, all meeting DSM-IV diagnostic criteria for schizophrenia and already treated with risperidone. In the experimental group (15), risperidone was changed to olanzapine to be administered for 8 weeks. Risperidone was maintained without a change in the daily dose in the control group (13). The assessment of clinical symptoms and cognitive functions in both groups was made at baseline and at 8 weeks. The experimental group relative to the control group showed significant improvement in five items such as immediate and delayed recall of verbal memory, verbal fluency, visual memory and total error of executive function. Although these data are preliminary, they could suggest the possibility of cognitive benefits from treatment with olanzapine relative to risperidone. These findings did not appear to be mediated by changes in clinical symptoms and side effects. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:265 / 269
页数:5
相关论文
共 50 条
  • [21] Initiation of olanzapine or risperidone: Effects on health outcomes among patients with schizophrenia
    Ren, XS
    Kazis, L
    Lee, AF
    Huang, YH
    Hamed, A
    Miller, DR
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 342 - 343
  • [22] The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia
    David, SR
    Taylor, CC
    Kinon, BJ
    Breier, A
    CLINICAL THERAPEUTICS, 2000, 22 (09) : 1085 - 1096
  • [23] Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia
    Citrome, L
    Volavka, J
    Czobor, P
    Sheitman, B
    Lindenmayer, JP
    McEvoy, J
    Cooper, TB
    Chakos, M
    Lieberman, JA
    PSYCHIATRIC SERVICES, 2001, 52 (11) : 1510 - 1514
  • [24] A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia
    Paul B. Fitzgerald
    Timothy L. Brown
    Jeff Z. Daskalakis
    J. Kulkarni
    Psychopharmacology, 2002, 162 : 74 - 81
  • [25] A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia
    Fitsgerald, PB
    Brown, TL
    Daskalakis, ZJ
    Kulkarni, J
    PSYCHOPHARMACOLOGY, 2002, 162 (01) : 74 - 81
  • [26] Differential effects of quetiapine, olanzapine and risperidone on glucose metabolism: A 24-week study in schizophrenia
    Brecher, M.
    Newcomer, J. W.
    Ratner, R. E.
    Eriksson, J. W.
    Emsley, R.
    Meulien, D.
    Miller, F.
    Risberg, S.
    Leonova-Edlund, J.
    Leong, R.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 423 - 423
  • [27] Risperidone, olanzapine, phenotiazines and neurosychological tests in schizophrenia
    Rybakowski, JK
    Borkowska, A
    BIOLOGICAL PSYCHIATRY, 2000, 47 (08) : 53S - 53S
  • [28] Risperidone and olanzapine drug outcomes study in schizophrenia: A developing country experience
    Sulaiman, AH
    Said, MA
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S241 - S241
  • [29] A double-blind study of combination of clozapine with risperidone in patients with schizophrenia:: Effects on cognition
    Akdede, Berna Binnur Kiviycik
    Yagcioglu, A. Elif Anil
    Alptekin, Koeksal
    Turgut, Tolga I.
    Tumuklu, Mevhibe
    Yazici, M. Kazim
    Jayathilake, Karu
    Tunca, Zeliha
    Gogus, Ahmet
    Meltzer, Herbert Y.
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (12) : 1912 - 1919
  • [30] Cost comparisons of olanzapine and risperidone in treating schizophrenia
    Liu, GG
    Sun, SX
    Christensen, DB
    Luo, XM
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (01) : 134 - 141